Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- MinuteCE®
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
0.75 program creditsJulia Brandts, MD
Prof. Alberto Zambon MD, PhD, FAHA
Prof. Kausik Ray, MBChB, MD, MPhil
Azfar Zaman, MD
John Kastelein, MD, PhD
- MinuteCE®
Understanding the role of triglycerides in the assessment of residual risk
0.50 program creditsProf. Alberto Zambon MD, PhD, FAHA